ABOUT AUTHORS
Suleman S. khoja * ¹, Dr. L J. Patel ², Sohil S. Khoja ³, Karim R. Panjwani ³, Jagdish Ray^3
1 PhD. Research Scholar, Ganpat University, Mehesana, Gujarat, India
² Faculty of Pharmacy, Ganpat University, Mehesana, Gujarat, India
³ Resource person, Pharmaceutical Quality Assurance, Audit and Compliance, Vapi, Gujarat, India

ABSTRACT
Good documentation constitutes an essential part of the quality assurance system and is key to operating in compliance with GMP requirements. Documentation requirements of maintaining complete, accurate, truthful and verifiable data in all cGXP documents that are needed to be maintained as per regulatory requirements and various Governmental regulations, laws, rules and statutes/acts. Documentation may exist in a variety of forms, including paper-based, electronic or photographic media. Ensure that the Document should be free from error and during any point if error identify then rectify with proper reason for correcting including sign and date. A system should be in place to indicate special observations and any changes to critical data. GMP Document must have predefined retention period and document must be stored in secure and easy to retrieve or easily available as and when required. Batch Processing and Packaging Instruction must be in place and Contemporaneous entry provision must be available. Instruction and procedure for using equipment; instrument must be clear and specific.  Specification with authorization should be available for analysis of Raw Material and Packing Material, Intermediate and Bulk Product, Finished Product.

{ DOWNLOAD AS PDF }

ABOUT AUTHOR
AK MOHIUDDIN
Faculty of Pharmacy, World University of Bangladesh

ABSTRACT
After liberation, Bangladesh pharma industry was largely dominated by the import dependent MNCs. On or before 1982 ordinance, 75% of the market was dominated by the MNCs and the rest share was with the other 133 local companies. After NDP formulation and the Drug Control Ordinance, there was a dramatic change of reverse. By 1994, a few pharma companies achieved a tremendous growth and they reinvest their profit for faster return. By next decade, Bangladesh is aiming to 30 world class drug manufacturers to establish strong footstep in global pharma market. Bangladesh, as an LDC got exempted from the obligation of patent and data protection in this arena until 2033. Interestingly, Bangladesh already passed across the LDC landmark to a developing country. So, there’s window of opportunity of more than a decade to grow further from that aspect.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
Mir Sahidul Ali¹, Souvik Mukherjee², Debayan Roy², Gargi Pal³, Subhajit Makar*^2
1Department of Chemical & Polymer Engineering, Tripura University (A Central   University), Suryamaninagar, Tripura 799022, India.
²School of Basic & Applied Sciences, Central University of Punjab,Bathinda-155110, Punjab, India.
³ Department of Pharmaceutical Sciences and Technology, NSHM Knowledge Campus, Kolkata- 700053, India.

ABSTRACT: Asparagus racemosus (A. racemosus) is a well-known medicinal plant due its various application in Ayurveda. It contains various type of secondary metabolite active natural products (or ingredients) such as steroids, alkaloids, flavonoids, furan derivatives and essential oils. In the present scenario due to growing catastrophic effect of diseases in human life, researchers are trying to stop synthetic drugs by replacing with herbal drugs. Herbal drug treatments are in general used to provide first-line and public health provider, both to persons abode in faraway areas the place it is the only on hand wellness service, and to people residing in bad areas the place it offers the one cheap relief. In this point of view A. racemosus can show a new path of herbal treatment.

{ DOWNLOAD AS PDF }

ABOUT AUTHORS
SPANDANA. M*, VAISHNAVI. M, PRAVALIKA. P, SUSMITHA. S, AMATUL ALI SAMEERA
Dept. of Pharmacy Practice
Sree Dattha Institute of Pharmacy,
Sheriguda (V), Ibrahimpatnam (M), Ranga Reddy, Telangana, India

ABSTRACT
AIMS AND OBJECTIVES: Our aim is to assess the clinical usage of Nebulization and Antibiotic therapy in COPD.
METHOD: An Observational, Prospective, Cohort study was conducted at a tertiary care teaching hospital, Telangana State, India. A total of 102 patients from the In-patient department of Pulmonology in Gleneagles Global Hospital, who were prescribed Nebulizers and Antibiotics and those who fulfilled the exclusion and inclusion criteria were selected for the study which was conducted for 6 months. All information significant to the study was collected from the case records and discussion conducted with the In-patients and bystanders during ward rounds with the support of a physician which were analyzed by SPSS software. Moreover daily follow-ups were conducted to assemble data on amendment in therapy, add on therapy, and clinical improvement.
RESULTS: The Mean age was 66 years and Standard Deviation was 13 years of the population. 41% were smokers and 27% were alcoholics. The most commonly used Bronchodilator is Duolin with a percentage of 96%. The most commonly used antibiotic is Magnex Forte with a percentage of 41.1%. The most commonly used formulation is Orals with a percentage of 53%. 92% of individuals responded in a positive way after the Nebulization therapy with Oxygen therapy provided to them, as their SpO 2 levels with oxygen therapy changed to normal range.
CONCLUSION: Nebulization therapy had more clinical improvement when compared to Inhalational therapy. The addition of corticosteroids had decreased the patient stay in hospital. Antibiotics added to the treatment decreased the frequency of exacerbations. Antibiotics added to the treatment decreased the frequency of exacerbations. The patient should be educated about the rational use of the drugs and decrease the risk and exacerbations of COPD.